<Record><identifier xmlns="http://purl.org/dc/elements/1.1/">URN:NBN:SI:DOC-J2CCWG55</identifier><date>2023</date><creator>Boltežar, Lučka</creator><creator>Gašljević, Gorana</creator><creator>Grčar-Kuzmanov, Biljana</creator><creator>Jezeršek Novaković, Barbara</creator><creator>Rožman, Samo</creator><relation>documents/doc/J/URN_NBN_SI_doc-J2CCWG55_001.pdf</relation><relation>documents/doc/J/URN_NBN_SI_doc-J2CCWG55_001.txt</relation><format format_type="type">article</format><format format_type="extent">Str. 14-19</format><identifier identifier_type="COBISSID_HOST">155264771</identifier><identifier identifier_type="URN">URN:NBN:SI:doc-J2CCWG55</identifier><language>slv</language><publisher publisher_location="Ljubljana">Onkološki inštitut</publisher><publisher publisher_location="Ljubljana">Združenje za radioterapijo in onkologijo pri Slovenskem zdravniškem društvu</publisher><source>Novosti na področju radioterapije in radiobiologije</source><rights>InC</rights><subject language_type_id="slv">kemoterapija</subject><subject language_type_id="slv">limfomi</subject><subject language_type_id="slv">onkološko zdravljenje</subject><title>Ali visoko maligni B-celični limfomi, dvojni ekspresorji, res potrebujejo intenzivnejšo kemoterapijo</title></Record>